Fundraising FoxSamsara BioCapital — 2024 Investments
8 investments dated 2024 · listed companies and verified rows first · show all
vTv Therapeutics is a biopharmaceutical company developing oral, small molecule drugs for diabetes and other chronic diseases.
BiotechDigital HealthMedical DevicesHigh Point, US
Rudy Howard(Executive Officer)inStephen Holcombe(Executive Officer)inLarry Altstiel(Executive Officer)Jeffrey Kindler(Executive Officer, Director)Paul Sekhri(Chairman, President, and Chief Executive Officer)inMichael Tung(Executive Vice President and Chief Financial Officer)in
Board seatSrinivas Akkaraju· per SEC Form D
Co-investorsJDRF T1D Fund
Enara Bio discovers and validates Dark Antigens from non-coding genomic regions to identify novel cancer targets, and develops first-in-class bispecific T-cell engagers against these targets through its EnTiCE platform.
BiotechDeep TechMedical Devices
George Kassiotis(Co-founder)Drew Pardoll(Co-founder)Houman Ashrafian(Co-founder)in
Co-investorsRA CapitalSV Health InvestorsPfizer VenturesDementia Discovery FundM VenturesPfizer Venture Investments
Alpha-9 Oncology develops radiopharmaceuticals for cancer treatment, with a portfolio of molecules in clinical and preclinical development.
BiotechDigital HealthMedical DevicesVancouver, CA
François Bénard(Founder)Kuo-Shyan Lin(Founder)David Perrin(Founder)
Co-investorsAndreessen HorowitzAscenta CapitalDelos CapitalFrazier Life SciencesGeneral CatalystLightspeed Venture Partners+9 more
.png)
Autobahn Therapeutics develops orally administered small molecule prodrugs using a brain-targeting chemistry platform to create regenerative medicines for central nervous system (CNS) disorders.
BiotechDeep TechMedical DevicesSan Diego, US
Kevin Finney(Chairman, President and CEO)inJohn Borkholder(Executive Officer)in
BoardKristina Burow(Director)inThomas Cahill(Director)Timothy Anderson(Director)Philip J DeSouza(Director)
Co-investorsARCH Venture PartnersCanaan PartnersMonograph Capital PartnersPfizer Venture InvestmentsInsight PartnersNewpath Partners
CandidRx develops T-cell engager antibodies to treat autoimmune diseases by redirecting T-cells to eliminate autoreactive B-cells.
BiotechHealthtechSan Diego, US
Ken Song(Chairman, President and CEO)inKenneth Song, M.D.(Executive Officer, Director)Arvind Kush(Executive Officer)Timothy Lu, M.D.(Executive Officer)inBernie Huyghe, Ph.D.(Executive Officer)
BoardJeffrey Tong, Ph.D.(Director)
Co-investorsForesite CapitalLifeSci Venture PartnersOrbiMedTCG CrossoverThird Rock VenturesvenBio Partners+2 more
Pathalys Pharma is a biotechnology company developing and improving therapeutic treatments for patients with chronic kidney disease.
BiotechHealthtechResearch Triangle Park, US
BT Slingsby(Co-Founder & Executive Chairman)in
Co-investorsAbingworthCatalys PacificOrbiMedKB Investment
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.